SCHEMBL2862983

SCHEMBL2862983

COc1ccc(-n2nc3c(c2N)c(=O)[nH]c2cc(O)ccc23)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.46
MAPT P10636 2/20 0.46
ALDH1A1 P00352 2/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
KMT2A Q03164 2/20 0.46
MEN1 O00255 1/20 0.46
POLB P06746 1/20 0.46
APEX1 P27695 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
ADORA3 P0DMS8 3/20 0.43
TDP2 O95551 1/20 0.41
KDM4E B2RXH2 1/20 0.41
ADORA1 P30542 1/20 0.40
RIOK2 Q9BVS4 1/20 0.40
XDH P47989 1/20 0.39
ESR1 P03372 1/20 0.39
LMNA P02545 1/20 0.38
ESR2 Q92731 1/20 0.38
ESRRA P11474 1/20 0.38
CA12 O43570 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2862177 0.90 ADORA3 (0.44) L3MBTL1KMT2AMEN1ADORA3TDP2
SCHEMBL2868711 0.88 TDP2 (0.47) KMT2AMEN1POLBADORA3TDP2
SCHEMBL2863002 0.86 KDM4E (0.39) GAAMAPTALDH1A1L3MBTL1KMT2A
SCHEMBL2868597 0.85 TDP2 (0.56) MAPTALDH1A1KMT2AMEN1POLB
SCHEMBL2866719 0.85 PDE2A (0.43) GAAMAPTALDH1A1KMT2AMEN1
SCHEMBL2864497 0.85 TDP2 (0.36) GAAMAPTALDH1A1L3MBTL1KMT2A
SCHEMBL2858978 0.84 ADORA3 (0.60) GAAMAPTALDH1A1L3MBTL1KMT2A
SCHEMBL2870382 0.83 BTK (0.47) ALDH1A1L3MBTL1KMT2AMEN1POLB
SCHEMBL2868587 0.81 KDM4E (0.38) GAAMAPTALDH1A1KMT2ATDP2
SCHEMBL2867124 0.79 TDP2 (0.47) GAAKMT2AMEN1POLBTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 US disclosed
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 US disclosed
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US disclosed
EP-1719771-A1 PYRAZOLOQUINOLONE DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2006-11-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof MAP3K20, MAP4K5, MAP4K3 GAA 4868/4885MAPT 4583/4885ALDH1A1 2391/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.